Literature DB >> 10194817

New strategies for combination vaccines based on the extended recombinant bacterial ghost system.

F O Eko1, A Witte, V Huter, B Kuen, S Fürst-Ladani, A Haslberger, A Katinger, A Hensel, M P Szostak, S Resch, H Mader, P Raza, E Brand, J Marchart, W Jechlinger, W Haidinger, W Lubitz.   

Abstract

Controlled expression of cloned PhiX174 gene E in Gram-negative bacteria results in lysis of the bacteria by formation of an E-specific transmembrane tunnel structure built through the cell envelope complex. Bacterial ghosts have been produced from a great variety of bacteria and are used as non-living candidate vaccines. In the recombinant ghost system, foreign proteins are attached on the inside of the inner membrane as fusions with specific anchor sequences. Ghosts have a sealed periplasmic space and the export of proteins into this space vastly extents the capacity of ghosts or recombinant ghosts to function as carriers of foreign antigens, immunomodulators or other substances. In addition, S-layer proteins forming shell-like self assembly structures can be expressed in bacterial candidate vaccine strains prior to E-mediated lysis. Such recombinant S-layer proteins carrying inserts of foreign epitopes of up to 600 amino acids within the flexible surface loop areas of the S-layer further extend the possibilities of ghosts as carriers of foreign epitopes. As ghosts do not need the addition of adjuvants to induce immunity in experimental animals they can also be used as carriers or targeting vehicles or as adjuvants in combination with subunit vaccines. Matrixes like dextran which can be used to fill the internal lumen of ghosts can be substituted with various ligands to bind the subunit or other materials of interest. Oral, aerogenic or parenteral immunization of experimental animals with recombinant ghosts induced specific humoral and cellular immune responses against bacterial and target components including protective mucosal immunity. The most relevant advantage of ghosts and recombinant bacterial ghosts as immunogens is that no inactivation procedures that denature relevant immunogenic determinants are employed in the production of ghosts. This fact explains the superior quality of ghosts when compared to other inactivated vaccines. As carriers of foreign antigens there is no limitation in the size of foreign antigens to be inserted and the capacity of all spaces including the membranes, periplasma and internal lumen of the ghosts can be fully utilized. Using the different building blocks and combining them into the recombinant ghost system represents a new strategy for adjuvant free combination vaccines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10194817     DOI: 10.1016/s0264-410x(98)00423-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

1.  Online monitoring of Escherichia coli ghost production.

Authors:  W Haidinger; M P Szostak; W Jechlinger; W Lubitz
Journal:  Appl Environ Microbiol       Date:  2003-01       Impact factor: 4.792

2.  Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate.

Authors:  F O Eko; D N Okenu; U P Singh; Q He; C Black; J U Igietseme
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

3.  Bacterial ghosts as an oral vaccine: a single dose of Escherichia coli O157:H7 bacterial ghosts protects mice against lethal challenge.

Authors:  Ulrike Beate Mayr; Christoph Haller; Wolfgang Haidinger; Alena Atrasheuskaya; Eugenij Bukin; Werner Lubitz; Georgy Ignatyev
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

4.  Purification and functional characterization of phiX174 lysis protein E.

Authors:  Yi Zheng; Douglas K Struck; Ry Young
Journal:  Biochemistry       Date:  2009-06-09       Impact factor: 3.162

5.  Diseases originate and terminate by genes: unraveling nonviral gene delivery.

Authors:  Rajan Swami; Indu Singh; Wahid Khan; Sistla Ramakrishna
Journal:  Drug Deliv Transl Res       Date:  2013-12       Impact factor: 4.617

6.  Hybrid biosynthetic gene therapy vector development and dual engineering capacity.

Authors:  Charles H Jones; Anitha Ravikrishnan; Mingfu Chen; Ryan Reddinger; Mahmoud Kamal Ahmadi; Snehal Rane; Anders P Hakansson; Blaine A Pfeifer
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-11       Impact factor: 11.205

7.  Generation of Salmonella ghost cells expressing fimbrial antigens of enterotoxigenic Escherichia coli and evaluation of their antigenicity in a murine model.

Authors:  Chan Song Kim; Jin Hur; Seong Kug Eo; Sang-Youel Park; John Hwa Lee
Journal:  Can J Vet Res       Date:  2016-01       Impact factor: 1.310

8.  Immunolocalization and challenge studies using a recombinant Vibrio cholerae ghost expressing Trypanosoma brucei Ca(2+) ATPase (TBCA2) antigen.

Authors:  Kiantra Ramey; Francis O Eko; Winston E Thompson; Henry Armah; Joseph U Igietseme; Jonathan K Stiles
Journal:  Am J Trop Med Hyg       Date:  2009-09       Impact factor: 2.345

Review 9.  Exploiting cholera vaccines as a versatile antigen delivery platform.

Authors:  Anisia J Silva; Francis O Eko; Jorge A Benitez
Journal:  Biotechnol Lett       Date:  2007-11-16       Impact factor: 2.461

10.  Escherichia coli ghost production by expression of lysis gene E and Staphylococcal nuclease.

Authors:  W Haidinger; U B Mayr; M P Szostak; S Resch; W Lubitz
Journal:  Appl Environ Microbiol       Date:  2003-10       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.